U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07049276) titled 'The Multicentre Selective Lymphadenectomy Trial - 3' on May 24.
Brief Summary: The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches for clinical Stage III melanoma. Following 6 weeks of standard neaodjuvant immunotherapy, patients will undergo either selective index lymph node resection (ILN) (identified at baseline as the largest affected lymph node) or the standard of care therapeutic lymph node dissection (TLND). The secondary aims are to assess if patients who are managed without TLND will have a reductio...